500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA
Announces Second Quarter 2026 Financial Results and Provides a Business Update
Ex-99.1
Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Kymera Therapeutics Elects Class III Directors at Annual Meeting
COO Jeremy Chadwick Resigns; Will Remain as Advisor Until November 2026
Announces First Quarter 2026 Financial Results and Provides a Business Update
Annual Report to Security Holders
News, Articles of Incorporation
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence